Nanomaterials for Cancer Precision Medicine

Abstract

Medical science has recently advanced to the point where diagnosis and therapeutics can be carried out with high precision, even at the molecular level. A new field of "precision medicine" has consequently emerged with specific clinical implications and challenges that can be well-addressed by newly developed nanomaterials. Here, a nanoscience approach to precision medicine is provided, with a focus on cancer therapy, based on a new concept of "molecularly-defined cancers." "Next-generation sequencing" is introduced to identify the oncogene that is responsible for a class of cancers. This new approach is fundamentally different from all conventional cancer therapies that rely on diagnosis of the anatomic origins where the tumors are found. To treat cancers at molecular level, a recently developed "microRNA replacement therapy" is applied, utilizing nanocarriers, in order to regulate the driver oncogene, which is the core of cancer precision therapeutics. Furthermore, the outcome of the nanomediated oncogenic regulation has to be accurately assessed by the genetically characterized, patient-derived xenograft models. Cancer therapy in this fashion is a quintessential example of precision medicine, presenting many challenges to the materials communities with new issues in structural design, surface functionalization, gene/drug storage and delivery, cell targeting, and medical imaging.

Cancer precision therapy necessitates the following critical components: new cancer classification based on oncogene identification; specific-oncogene-targeted therapy by noncoding RNAs; gene-delivery via advanced and programmable nanocarriers, and accurate assessment of drug efficacy by genetically characterized patient-derived xenograft (PDX) models. The major critical issues involved in all aspects of cancer precision medicine and nanomaterials science are addressed.

http://ift.tt/2D0LYpj